Hilal Ozdag

Summary

Publications

  1. ncbi Differential expression of selected histone modifier genes in human solid cancers
    Hilal Ozdag
    Department of Oncology, Hutchison MRC Research Centre, University of Cambridge, Cambridge CB2 2XZ, UK
    BMC Genomics 7:90. 2006
  2. ncbi A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes
    Maria J Garcia
    Department of Oncology, Hutchison MRC Research Centre, Cancer Genomics Program, University of Cambridge, Hills Road, Cambridge CB2 2XZ, UK
    Oncogene 24:5235-45. 2005
  3. ncbi p300 regulates p53-dependent apoptosis after DNA damage in colorectal cancer cells by modulation of PUMA/p21 levels
    N Gopalakrishna Iyer
    Cancer Genomics Program, Department of Oncology, University of Cambridge, Hutchison MRC Research Centre, Hills Road, Cambridge CB2 2XZ, United Kingdom
    Proc Natl Acad Sci U S A 101:7386-91. 2004
  4. ncbi p300/CBP and cancer
    Narayanan Gopalakrishna Iyer
    Cancer Genomics Program, Department of Oncology, University of Cambridge, Hutchison/MRC Research Centre, Cambridge CB2 2XZ, UK
    Oncogene 23:4225-31. 2004

Collaborators

Detail Information

Publications4

  1. ncbi Differential expression of selected histone modifier genes in human solid cancers
    Hilal Ozdag
    Department of Oncology, Hutchison MRC Research Centre, University of Cambridge, Cambridge CB2 2XZ, UK
    BMC Genomics 7:90. 2006
    ..Expression of each gene in 225 samples (135 primary tumours, 47 cancer cell lines, and 43 normal tissues) was analysedby QRT-PCR, normalized with 8 housekeeping genes, and given as a ratio by comparison with a universal reference RNA...
  2. ncbi A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes
    Maria J Garcia
    Department of Oncology, Hutchison MRC Research Centre, Cancer Genomics Program, University of Cambridge, Hills Road, Cambridge CB2 2XZ, UK
    Oncogene 24:5235-45. 2005
    ....
  3. ncbi p300 regulates p53-dependent apoptosis after DNA damage in colorectal cancer cells by modulation of PUMA/p21 levels
    N Gopalakrishna Iyer
    Cancer Genomics Program, Department of Oncology, University of Cambridge, Hutchison MRC Research Centre, Hills Road, Cambridge CB2 2XZ, United Kingdom
    Proc Natl Acad Sci U S A 101:7386-91. 2004
    ..When xenografted, p300(-) cells are more sensitive to chemotherapy with doxorubicin. These results show that p300 is a key regulator of the p53 response and suggest that p300 inhibition could be used to modulate chemotherapy...
  4. ncbi p300/CBP and cancer
    Narayanan Gopalakrishna Iyer
    Cancer Genomics Program, Department of Oncology, University of Cambridge, Hutchison/MRC Research Centre, Cambridge CB2 2XZ, UK
    Oncogene 23:4225-31. 2004
    ..The involvement of these proteins in critical tumorigenic pathways (including TGF-beta, p53 and Rb) provides a mechanistic route as to how their inactivation could result in cancer...